A new resource for breast cancer patients

Treatment with Enhertu “is an unprecedented approval” for patients with HER2-positive solid tumors who did not have many options, an expert told CURE®.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

The FDA has granted accelerated approval to Ojemda for patients 6 months and older with relapsed or refractory pediatric low-grade glioma with a BRAF fusion or rearrangement, or BRAF V600 mutation.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

Lutathera was approved for patients 12 or older with SSTR-positive gastroenteropancreatic neuroendocrine tumors, the FDA announced.

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.